Abstract | Reproductive hormones affect all stages of life from gamete production, fertilization, fetal development and parturition, neonatal development and puberty through to adulthood and senescence. The reproductive hormone cascade has, therefore, been the target for the development of numerous drugs that modulate its activity at many levels. As the central regulator of the cascade, gonadotropin-releasing hormone (GnRH) agonists and antagonists have found extensive applications in treating a wide range of hormone-dependent diseases, such as precocious puberty, prostate cancer, benign prostatic hyperplasia, endometriosis and uterine fibroids, as well as being an essential component of in vitro fertilization protocols. The neuroendocrine peptides that regulate GnRH neurons, kisspeptin and neurokinin B, have also been identified as therapeutic targets, and novel agonists and antagonists are being developed as modulators of the cascade upstream of GnRH. Here, we review the development and applications of analogues of the major neuroendocrine peptide regulators of the reproductive hormone cascade: GnRH, kisspeptin and neurokinin B.
Introduction
The development of synthetic molecules that modulate reproductive hormone levels has had a major effect on our lives. Arguably, the development of the female contra ceptive pill was the single most important contribution to the empowerment of women and their increased par ticipation in professional and public life. On the other hand, anabolic steroids are the most utilized enhancer of competitive athletic performance, whilst estrogen and androgen antagonists, and inhibitors of their synthesis and bioconversion, are extensively employed as thera peutics for breast and prostate cancers-two of the most prevalent cancers in men and women. A wide range of tissues are stimulated by sex steroid hormones, and a large number of hormonedependent diseases arise from dysfunctional sex hormone stimulation. These diseases include benign prostatic hyperplasia, bone loss, endo metriosis, polycystic ovary syndrome (PCOS), uterine fibroids, ovarian cancer, muscle wasting and various aspects of metabolic and cognitive dysfunction (Box 1).
Regulation of the reproductive system is initiated by an array of external and internal inputs, such as photo period, metabolic products and nutrients, growth factors, stress, infection and inflammation, as well as many central and peripheral growth factors and hor mones. These inputs are integrated in the brain and hypothalamus to regulate the biosynthesis and secretion of gonadotropinreleasing hormone (GnRH; Figure 1 ). GnRH is conducted by portal vessels to the anterior pituitary where it engages the GnRH receptor (GnRHR) in gonadotrope cells to recruit intracellular signalling machinery that stimulates the biosynthesis and secre tion of the gonadotropins luteinizing hormone (LH) and folliclestimulating hormone (FSH).
1,2 LH and FSH then act on the ovary and testis to stimulate the production of gametes and steroid and peptide hormones. These hor mones feed back in a positive and negative manner at the hypothalamus and pituitary to regulate the reproductive hormone cascade. 1, 3 The diverse external and internal factors regulating GnRH do so through a complex network of neuro transmitters and neuropeptides in the central nervous system (CNS) and hypothalamus. [3] [4] [5] In humans, inactivat ing mutations of two of these neuropeptides, kiss peptin and neurokinin B, or their cognate recep tors results in a failure to progress through puberty and in adult infertility, highlighting the crucial role of these neuro peptides in GnRH neuron activation. [6] [7] [8] [9] [10] [11] In addition to these major modulators of GnRH secretion, neuropeptide Y, products of the pro opiomelanocortin protein, gonadotropininhibitory hormone (GnIH) and neurotransmitters (such as γamino butyric acid and glu tamate) also regulate GnRH neuron activity. 12, 13 All of the hormones in the cascade from the brain to the pituitary, gonads and peripheral tissues are potential targets for the development of analogues that modulate the production of gametes and sex steroid hormones that have an effect on diverse target tissues. The sites of current and poten tial intervention in the reproductive hormone cascade are indicated in Figure 1 .
Sex steroid agonists, antagonists and inhibitors of their synthesis have been extensively employed for contraception and hormonedependent diseases over many years. GnRH and its analogues have similarly received wide application in hormonedependent dis eases. Natural and recombinant gonadotropins are the mainstay of treatment of delayed puberty, infertility and assisted reproductive technologies such as in vitro ferti lization (IVF), in which they are used along with GnRH analogues that suppress endogenous gonado tropin. The neuropeptides kisspeptin, neurokinin B and GnIH, which regulate GnRH neurons, are cogent targets for regulation Key points ■ The reproductive hormone cascade from the brain to the pituitary, gonads and peripheral tissues provides numerous target points for therapeutic intervention in diseases ■ Hormones in the cascade include the neuropeptides kisspeptin and neurokinin B, which regulate hypothalamic gonadotropin-releasing hormone (GnRH); in turn, GnRH stimulates gonadotropins and downstream sex steroid hormones that affect most tissues ■ Modulation of sex steroid hormone levels in contraception, infertility and hormone-dependent diseases (for example, prostate cancer, endometriosis, uterine fibroids and polycystic ovary syndrome) is achieved through steroid hormone and GnRH analogues ■ Novel, orally active GnRH analogues are providing a new dimension in dose regulation for patients who require partial inhibition of sex steroids ■ Kisspeptin and neurokinin B represent new therapeutic targets; analogues have been developed that herald a new era of subtle regulation of the reproductive hormone cascade ■ The enlarged armamentarium of molecules regulating reproductive hormone levels promises to deliver improved control of reproduction and treatment of diseases that impinge on all stages of the human life span of the reproductive system; however, the use of agonist and antagonist analogues of these neuro peptides as regu lators of the reproductive system has been restricted to animal studies. Nevertheless, neuro kinin B and GnIH analogues have been studied in humans, albeit with a focus on therapeutic applications in CNS dysfunction, such as pain and schizophrenia. Thus, these analogues have already met regulatory requirements for use in humans and are available to 'fasttrack' clinical research into the role of these neuropeptides in the reproductive system in humans. A review on all the hormone analogues in the entire reproductive hormone cascade (Figure 1 ) would be excessively vast; therefore, the current Review focuses on analogues of the neuroendocrine peptides, GnRH, kisspeptin and neurokinin B. Only brief background to the discovery and physiology of the peptides is given, as reference is made to existing comprehensive reviews.
GnRH analogues
Background GnRH, the central initiator of the reproductive hor monal cascade, was first isolated from mammalian hypothalami as the decapeptide pGluHisTrpSerTyr GlyLeuArgProGlyNH 2 .
14-16 GnRH is syn thesized in approximately 1,000 specialized neurons of the hypothalamus by enzymatic processing of a precursor protein. It is transported down axons of GnRH neurons to the median eminence, from where it is released in a pulsatile manner into the hypophyseal portal system to stimulate synthesis and secretion of LH and FSH from pituitary gonadotrope cells. 1, 2 GnRH pulses are released every 30-120 min. Each GnRH pulse stimulates a pulse of LH secretion, whilst FSH pulses are less clear, partially because of the longer halflife of FSH compared with LH. In men, GnRH is released in pulses of constant frequency. However, in women, the frequency of GnRH pulses changes over the menstrual cycle, with the highest frequency at the LH surge of ovulation and the lowest frequency during the luteal phase of the ovarian cycle. These variations in GnRH pulse frequency, in addition to modulation of the LH and FSH responses to GnRH by gonadal steroid and peptide hormones, result in an asynchronous pattern of LH and FSH release. Moreover, whereas LH is stored within the gonadotrope cells and its secretion is largely dependent on GnRH, FSH is constitutively secreted and more dependent on biosynthesis than on GnRH.
GnRH peptide agonists and antagonists
The primary structure of GnRH isolated from pigs and sheep (pGluHisTrpSerTyrGlyLeuArgProGly NH 2 ) was initially thought to be conserved through out vertebrates. However, the demonstration that bird, fish and reptile GnRH had different properties 17 led to the structural elucidation of a novel form of GnRH in ch ickens, 18, 19 and subsequently to the discovery of an array of structures in vertebrates and invertebrates. 17, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] These structural variants reflect 'experiments of nature' over 600 million years of evolution and provide insight into conserved and functionally important residues and domains. The structures reveal that the amino (pGlu HisTrpSer) and carboxyl terminal (ProGlyNH 2 ) domains are highly conserved, which indicates that they are important for receptor binding and activation. Glycine at position 6 in the middle of the molecule is also highly conserved in vertebrates and facilitates folding of the peptide (see below). The amino acid in position 8 is the most variable, with arginine 8 in mammalian GnRH being essential for high affinity binding to mam malian receptors through interaction with an acidic residue in extracellular loop 3 of the GnRH receptor. 35 Physicochemical studies using tryptophan fluores cence, conformational memory simulations, NMR imag ing and ion mobility mass spectrometry have indi cated that mammalian GnRH assumes a folded confir mation around glycine 6. This conformation is depicted in the NMR structure in Figure 2 , which shows the amino and carboxyl termini are closely apposed, ena bling these conserved domains to bind and activate the receptor. The achiral glycine at position 6 facilitates the formation of a structure known as a βII' type turn, in which a region of the peptide involving four consecu tive amino acids folds back on itself by nearly 180°. This structure is conserved in the GnRHs of most vertebrates. Substitution of glycine 6 with chiral amino acids, as is present in the GnRHs of jawless fish and invertebrates, leads to a large decrease in binding affinity at the mam malian GnRHR. Conversely, the substitution of the chiral amino acids in position 6 of sea squirt GnRHs with glycine increases the binding affinity of these GnRHs at the mammalian receptor. 36 If glycine at position 6 of human GnRH is substituted with a damino acid the βII' confirmation is enhanced and binding affinity is increased. 37 This feature is incor porated in all GnRH analogues ( Figure 3 ). Substitutions of glycine at position 6 with damino acids containing large aromatic side chains, such as dtryptophan (as in the drug, triptorelin), increases binding affinity com pared with GnRH by about 100fold, whereas substitu tion with dleucine (as in the drug, leuprorelin) only increases affinity about 10fold. Substitutions at this position have the added advantage of conveying resist ance to proteolytic cleavage. Incorporation of damino acids with large hydrophobic side chains (for example, dtryptophan) also results in the binding of GnRH to plasma proteins such as albumin, thus further enhanc ing its halflife in the circulation and decreasing meta bolic clearance. 38 Substitution of the carboxyl terminal GlyNH 2 with alkyl moieties (for example, ethylamide) conveys further resistance to proteolysis without com promising binding affinity. 38 Thus, the different sub stitutions described here form the basis of all GnRH peptide analogues.
Studies involving systematic substitutions of all GnRH amino acids established that substitutions in the amino terminal domain resulted in retention of binding affin ity but reduced receptor activation and represented the first antagonists. 38 Further experimentation with multiple substitutions at the amino terminal domain, particularly with unnatural damino acids (such as dnapthyl alanine) produced analogues with very high binding affinity (<1 nM) and full antagonist properties. All antagonists have substitutions with bulky hydro phobic damino acids in positions 1, 2 and 3 (and some in 4) that maintain high binding affinity but ablate GnRHR activation. 38, 39 GnRH peptide agonists and antagonists that are used in clinical practice or are in clinical development are shown in Figure 3 .
Nonpeptide antagonists
The development of nonpeptide, orally bioavailable GnRH antagonists has been pursued by most large pharma ceutical companies as well as a number of bio technology companies in order to overcome the require ment of injection of peptide antagonists. Furthermore, orally active molecules provide the potential for titrating 40 The binding sites of the nonpeptide GnRH antagonists seem to overlap with each other, but also to a considerable extent with the orthosteric binding site of GnRH. Thus, aspartic acid 302, asparagine 212 and tyrosines 283/284 of the GnRHR, which were all identified as inter acting sites for GnRH, are proposed sites of interaction with the nonpeptide antagonists. 3, 41, 42 Figure 4 shows a summary of the optimal pharmacophore for nonpeptide antago nists interpreted from the data. The pharmacophore contains three heterocyclic aromatic rings, a basic nitrogen (hydrogenbond donating) group and an ester ( hydrogenbond accepting) group, which have possible interactions with phenylalanine 309, tyrosine 211, tyro sines 283/284, aspartic acid 302 and asparagine 212 of the human GnRHR receptor pocket, respectively.
Although a large spectrum of nonpeptide antagonists have been developed and patented, only two, TAK385 and elagolix, have entered the clinic (Figure 4 ). These compounds exhibit high receptorbinding affinity, and good bioavailability, pharmacokinetic and pharmo dynamic profiles, and dose-response relationships. [43] [44] [45] The primary therapeutic target of elagolix is currently endometriosis, but a clear possibility exists for applica tion in PCOS and IVF, as well as for partial androgen suppression in benign prostatic hyperplasia (as dis cussed later). Although these smallmolecule GnRH antagonists have the advantage of oral activity and dosing to achieve the desired degree of steroid hormone inhibition, the peptide analogues have potentially fewer offtarget adverse effects than the small molecules, as they are modified versions of the natural hormone, which has been highly selected during evolution to specifically target the cognate receptor. Although a large range of smallmolecule GnRH antagonists have been developed, so far no attempts have been made to produce nonpeptide agonists for clinical application.
Nonpeptide GnRH antagonists as pharmacoperones
Cellsurface expression of the human GnRHR is low compared with that in other species, 46 and this low expression is further reduced in patients with hypo gonadotropic hypogonadism who harbour mutations in the GnRHR that result in misfolding of the recep tor. 3 These misfolded mutant receptors are recognized by intracellular 'quality control' components and are retained intracellulary and targeted for degradation rather than being trafficked to the cell surface. The majority of GnRHR mutations give rise to poor cell surface expression as opposed to a loss of binding or signalling. Some nonpeptide GnRH analogues are able to penetrate into the cell, bind to the nascent receptors and stabilize the folding of the mutant GnRHRs thereby, acting as 'pharmacoperones' to increase mutant receptor cellsurface expression.
47,48
GnRH/GnRH-R interactions and desensitization GnRHR was first cloned from a mouse gonadotrope cell line 49 and subsequently from a large range of mammals, vertebrates and invertebrates. 3, 33 The receptor is a member of the rhodopsin family of Gproteincoupled receptors (GPCRs) with the characteristic seven trans membrane domains connected by extracellular loop and intracellular loop domains. A unique feature of GnRHR is the absence of a carboxyl terminal tail, which is the domain of GPCRs that is responsible for rapid (within minutes) ligandinduced desensitization to terminate signalling. Thus, the GnRHR is not rapidly desensitized, probably to facilitate prolonged LH secretion, which is necessary for ovulation. 50 Nevertheless, prolonged expo sure (1-3 weeks) to GnRH agonists induces a decline in circulating levels of gonadotropin and sex steroids in humans. The application of longterm desensitization utilizing GnRH agonists is described below.
The mechanism by which GnRH agonists desensi tize the GnRHR is widely regarded as being through receptor 'downregulation' . This assumption is evidently incorrect, as the actions of the agonists would be nulli fied if there were a decline of GnRH receptors on which to act. The mechanisms of desensitization are multiple and cannot be described here in detail. However, they include uncoupling of the GnRHR from Gproteins, downstream signalling, calcium mobilization and protein kinase activation. For example, the capacity of inositol trisphosphate (generated by GnRH receptor acti vation) to mobilize intracellular Ca 2+ is desensitized after prolonged receptor activation. The gonadotrope cell does continue to respond to GnRH agonist but fails to secrete biologically active gonadotropins. These responses are evident from the elevated levels of circulating gonado tropin αsubunits but the diminished levels of biologi cally active gonadotropin heterodimers consisting of α and β subunits in patients receiving longterm GnRH agonist treatment. 51 Thus, effective receptor is present, but recruitment of biosynthetic and/or exocytotic machinery is altered.
Knowledge of the 3D structure of the GnRHR is essential for a complete understanding of its molecu lar function and binding to GnRH. In the absence of a crystal structure of the GnRHR, molecular models of the receptor based on the crystal structures of other GPCRs, such as rhodopsin and the β 2 adrenergic receptor, have been constructed. 3, 52 The validity of the GnRHR structural model has been tested by extensive mutagenesis to identify putative interacting residues. In this way, a reliable model of the GnRHR has been built, and binding sites of GnRH in the GnRHR have been identified. The NMR structure of GnRH has been satisfactorily docked to the GnRHR structure to accom modate all of the interactions of the ligand and recep tor ( Figure 5 ). 52 The cloning of the GnRHR has been crucial for the development of nonpeptide antagonists, and knowledge of the interaction of GnRH with GnRHR has guided the development of GnRH analogues.
Therapeutic applications
Pulsatile delivery of 100 μg per h of native GnRH (to simu late hypothalamic release) has been successfully used to stimulate fertility in patients with hypothalamic hypo gonadism resulting from congenital conditions, such as Kallman syndrome, and nutritional conditions, such as anorexia nervosa, obesity and diabetes mellitus. This treatment modality is also effective in stimulat ing testis descent in patients with cryptorchidism and delayed puberty. 25, [53] [54] [55] [56] [57] [58] In contrast to these stimulatory uses of native GnRH, both agonists and antagonists are admini stered to inhibit gonado tropins and sex steroid secretion; agonists through gonadotrope desensitization and antagonists through direct inhibition of endogenous GnRH binding and activation of the GnRH receptor. GnRH analogues are, therefore, extensively employed in treating hormonedependent diseases and in preventing ovulation and aiding oocyte retrieval in assisted repro ductive technologies such as IVF. As such they constitute a market in excess of US$2 billion worldwide.
A disadvantage of GnRH agonists is the initial stimu lation of gonadotropin and sex steroids for the first 1-2 weeks before the onset of desensitization. This feature results in the 'flare' of the condition in hormone dependent diseases. The flare period can be managed by concurrent administration of steroid antagonists or inhibitors of steroid biosynthesis. A further dis advantage is that desensitization with agonists requires a longer treatment period when used for the induction of fol licle development and oocyte retrieval in IVF than that required when using GnRH antagonists. Thus agonists are being replaced with antagonists for this procedure.
GnRH antagonists do not induce disease flare, as there is an immediate inhibition of gonadotropin and sex st eroids, with a brief delay (a few hours) correspond ing to the halflife of the hormones. Firstgeneration GnRH antagonists produced a concerning histaminic reaction. This reaction was due to a basicxbasic amino acid motif. Consequently, current antagonists that have entered the clinic avoid this structural feature and are free of histaminic activity. 59 The main disadvantage of GnRH antagonists, compared with agonists, is that much higher doses are required to continually compete with endogenous GnRH, the levels of which increase owing to the decline in sex steroid levels and concomitant removal of negative feedback on GnRH secretion. Thus, monthly depot preparations of GnRH antagonist contain about 100 mg in contrast to monthly preparations of 3-5 mg of GnRH agonists. A perceived disadvantage of GnRH peptide analogues is the requirement to administer them by injection, as they are proteolytically cleaved in the digestive tract and are, therefore, not orally bioavailable. However, this dis advantage is compensated by their formulation as slowrelease depot preparations that require infrequent admini stration (1 injection per month to 1 injection per year) and ensure patient compliance. GnRH agonists such as triptorelin, goserelin and leupro relin are formulated as slowrelease depot preparations in bio degradable poly mers (for example, polyglycyl lactide copolymer). When injected intramuscularly, these slowrelease prepara tions of GnRH agonists (about 3-5 mg) release approxi mately 100 μg per day for a month. Some prepara tions (for example, histrelin) are capable of suppressing gonado tropin levels for 12 months. 60 GnRH antagonists have been similarly formulated.
As the objective of GnRH analogue therapy in hormonedependent cancers is to reduce the level of sex steroid hormones to castration levels, expected adverse effects in prolonged treatment are hot flushes, vaginal dryness, irregular vaginal bleeding, loss of libido, decreased lean body mass and bone loss. These symp toms can be alleviated by intermittent treatment with GnRH analogues or by 'add back' therapy with appro priate sex steroid hormones (for example, lowdose estrogen in women being treated for endometriosis or those who experience bone loss [61] [62] [63] . A novel approach to the undesired adverse effects of GnRH analogues is the development of bifunctional conjugates of GnRH analogues in which the position 6 damino acid is con jugated to the appropriate sex steroid. These conjugates retain full GnRH analogue and steroid activity within a single molecule. 64 Of all the therapeutic applications of GnRH analogues, their use in prostate cancer is by far the greatest, and these analogues are the preferred therapeutic treatment for this condition. 65 A marked increase in survival, and a reduction in the levels of prostatespecific antigen and pain is observed in men with prostate cancer treated with GnRH analogues. GnRH analogues are also employed in almost all cycles of IVF treatment to avoid the sponta neous LH surge and loss of oocytes before laproscopic surgery for oocyte retrieval. 66 In all other applications of GnRH analogues, alternative therapeutic approaches are available. 67 Among benign conditions, endometriosis has a prevalence of 6-10% in all women and 20-40% in infer tile women. Improvement in pain is reported in 75% of women with endometriosis treated with GnRH ana logue therapy, but no improvement in pregnancy rates has been observed. 61 GnRH analogue therapy has also been reported to be beneficial in a range of other hormone dependent conditions in women, including PCOS, which is the most common endocrine disorder in women, 68 uterine fibroids (the most common solid tumour in women) 69 and dysfunctional uterine bleeding. 70 GnRH analogues have also been employed with success in hormonedependent malignancies in women. GnRH analogue combined with antiestrogen was more effective than either treatment alone in metastatic breast cancer in premenopausal women with estrogen receptorpositive disease. 71 Ovarian and endometrial cancers seem to express GnRH and GnRHR, and there are indications that treatment with GnRH and its analogues results in cell cycle arrest leading to anti proliferative effects. 72 Efficacy in ovarian cancer treatment has also been demon strated in clinical trials using GnRH analogues. 73 A number of studies have also used GnRH analogues to inhibit gonadal activity in an attempt to protect the gonads before cyto toxic chemotherapy, but the ef fectiveness of this approach is still uncertain.
Kisspeptin analogues
Background Although the GnRH neuron is the final neuroendocrine conduit for the influence of diverse internal and external factors regulating reproduction, the absence of receptors for these inputs on GnRH neurons presented a conun drum. In particular, sex steroid hormone receptors, which are required for negative and positive feedback by steroids on GnRH secretion, are largely absent from GnRH neurons. This observation suggested the exist ence of steroidresponsive neurons that regulate GnRH neurons. A breakthrough in identifying such neurons occurred with the observation that inactivating muta tions in genes encoding the human and mouse kisspeptin receptors (GPR54/Gpr54) resulted in a failure to progress through puberty. 6, 7 An inactivating mutation in the human gene encoding kisspeptin (KISS1) also resulted in a failure to achieve puberty. 8 The discoveries that the kisspeptins and their cognate receptor GPR54 have a key neuroendocrine role in the regulation of reproduction 7 is regarded as a milestone of equivalent importance to the discovery of GnRH more than three decades ago.
Kisspeptins are members of a family of peptide hor mones known as RFamides, which are characterized by an ArgPheNH 2 carboxylterminal motif. These peptides are involved in numerous physiological and pathophysio logical processes including control of food intake, pain, inflammatory responses, development and metabolism. 75 Kisspeptin was initially termed metastin owing to its activity in inhibiting metastasis of melanoma cells. 76, 77 The KISS1 gene transcribes a 145 amino acid poly peptide with a signal sequence, followed by a 119 amino acid sequence that is processed to a 54 amino acid peptide in humans. The human 54 amino acid peptide and rodent 52 amino acid peptide are further proteo lytically processed to carboxylterminal peptides of 14, 13 and 10 amino acids, all of which are biologically active. 76 The 10 amino acid peptide (Kp10) has full intrinsic biological activity. 77, 78 However the 54 or 52 amino acid peptides have longer halflives and, therefore, increased LHreleasing activities than the shorter forms in vivo. 79, 80 Kp10 is a potent stimulator of LH, FSH and gonadal steroid secretion when administered both centrally and systema tically. [81] [82] [83] [84] Kisspeptin stimulation of gonado tropins is ablated by coadministration of GnRH antago nist, demonstrating that kisspeptin acts through the stimu lation of GnRH secretion. 85 Moreover, GnRH neurons express GPR54, 86 and kisspeptin stimulates GnRH secretion. 87 Intravenous infusion of Kp54 to men increases circulating levels of LH and FSH. 88 Acute intra venous administration of Kp10 has similar stimu latory effects on gonadotropin secretion in men over a dose range of 0.01-1.00 μg/kg. 89, 90 The stimulatory effect of kiss peptin administration in premenopausal women is greatest during the preovulatory phase of the menstrual cycle. 91 Importantly, neurons that express kisspeptin also express steroid hormone receptors. [92] [93] [94] [95] Gonadectomy in rodents increases detectable numbers of neurons that express kisspeptin and mRNA expression levels of kiss peptin in the arcuate nucleus (ARC), whereas steroid replacement therapy produces the opposite effects. 94, 95 Whilst kisspeptinexpressing neurons in the ARC mediate this steroid negative feedback control on GnRH neurons, another population of kisspeptinexpressing neurons in rodents in the anteriorventral para ventricular nucleus mediates positive feedback, which results in the ovulatory LH surge. [94] [95] [96] [97] This anatomically linked functional dimorphism of kisspeptin neurons is not evident in sheep or monkeys, as both types of neurons in these animals seem to be localized in the ARC. 92, 98, 99 In order to ensure survival of offspring, reproduction is finely tuned to the availability of nutrients and meta bolic status. Kisspeptin seems to have a major mediating role in the dialogue between nutrition and metabolism with reproduction. 5 This relationship is of particular relevance in the context of the rising global prevalence of obesity and secondary pathologies, such as diabetes mellitus. A considerable body of data supports a central role of kisspeptin and GPR54 in mediating the effects of metabolism on the reproductive system. 5, 100, 101 A link between leptin secretion from adipose tissue and expression of the KISS1 gene is suggested by the obser vation that KISS1 expression in the ARC is reduced in castrated leptindeficient ob/ob mice, and is increased by administration of leptin to these mice. 102 Although initial studies reported expression of leptin receptors on kisspeptin neurons, 102 Donato et al. found that de letion of the leptin receptor in hypothalamic kiss peptin neurons in mice had no effect on puberty or fertility, which indicates that direct leptin signalling in KISS1 neurons is not required for these processes. 103 However, bilateral lesions of the ventral premammillary nucleus of ob/ob mice blunted the capacity of exogenous leptin to induce sexual maturation. 103 Experimental diabetes mellitus induced by strep tozotocin administration in rats reduces kisspeptin mRNA expression and gonadotropin secretion. 104 Fast ing reduces kisspeptin mRNA expression in the rat hypothalamus, and kisspeptin administration reverses starvationinduced hypogonadotropism, 105 and GPR54 mRNA expression is similarly affected in mice. 102 On the basis of these findings in animal studies, hypotheses proposing a role of kisspeptin signalling in mediating hypogonadotropic hypogonadism in diabetes mellitus and obesity in humans have been articulated. 89 Metabolic effects on reproduction in humans that could involve kisspeptin dysregulation include hypothalamic amenor rhoea (anorexia nervosa being an extreme example) and PCOS, which is charac terized by increased LH pulse fre quency and is often associated with obesity. 68 A diversity of physiological and pathophysiological effects modulate the kisspeptin system, and these have been thoroughly reviewed elsewhere. 77, 106, 107 Kisspeptin peptide agonists Two approaches have been employed in the development of kisspeptin peptide analogues. The first approach was alanine scanning, in which each amino acid residue of Kp10 was systematically substituted with alanine (which lacks a functional side chain), thus revealing whether the side chain was of importance or not. This approach revealed that alanine substitutions for phenyla lanine at positions 6 and 10 of Kp10 considerably reduced binding and activation of GPR54 in vitro and in vivo. This finding indicated that aromatic side chain groups in amino acids in these positions are required for activ ity. 108, 109 Substitution of arginine at position 9 with alanine also considerably decreased binding and activa tion, as did substitution of leucine at position 8. Thus, phenylalanine 6, arginine 9 and phenylalanine 10 appear to constitute a binding pharmacophore. 108 The second approach, which utilized knowledge of the structure of Kp10, involved creating conserva tive changes at target positions of Kp10. Examples of changes included changing the side chain but not the overall charge of an amino acid residue, substituting lamino acids with damino acids to assess the position ing of side chains, and making radical structural changes to modify overall charge or flexibility of the analogue. Substitution of arginine 9 and phenylalanine 10 led to a loss in binding, which confirmed the importance of these conserved residues. 110, 111 Systematic natural and unnatural amino acid substitu tion was used in the development of kisspeptin peptide agonists to target cancers and hormonedependent disease. 112, 113 These studies and data in patents con firmed that the critical pharmacophore of phenylala nine 6, arginine 9 and phenylalanine 10 must be retained or altered with conservative amino acid substitutions. Other positions in the Kp10 amino acid sequence were subject to a range of substitutions to provide resistance to degrada tion and improved pharmacokinetics. A series of agonists of GPR54 were produced that provided potent inhibition of cancer cell growth and stimulation of reproductive hormones. 112, 113 Two of these peptide agonists of GPR54 (KISS1305 and TAK448) have been studied in rats for shortterm gonadotropin and steroid hormone stimulation and longterm inhibition through desensitization. 114 With both analogues, testosterone was reduced to castration levels within 3 days and remained depleted through out the 4week treatment period. The mechanism of desensitiza tion seemed to be predominantly at the level of the GnRH neuron. Remarkably, the suppression of testos terone levels was apparently faster and more pro nounced, and reproductive organ weights more reduced, than after administration of the GnRH analogue, leu prorelin. This result is unexpected, as kisspeptin stimula tion of LH in humans and animals is much less than that of GnRH, and kisspeptin antagonists only partially sup press LH, which suggests that a kisspeptinindependent component of GnRH secretion exists. 111, 115 Thus, effects of desensitization with kisspeptin agonists would be expected to be less than that of GnRH agonists.
Kisspeptin peptide and nonpeptide antagonists
In all of the studies on the physiological and patho physiological regulation of kisspeptin, the end point measures were kisspeptin mRNA and/or kisspeptin pep tide concentrations in tissue. No direct evidence, therefore, exists that these manipulations alter the secretion of kisspeptin. An exception is a single study in female rats, which demonstrated that kisspeptin anti serum inhibits the ovulatory LH surge, 116 implying that increased kisspeptin secretion elicits the surge.
To directly elucidate the role of kisspeptin secretion and GPR54 activation in physiological processes, the develop ment of kisspeptin antagonists is essential. An understanding of the structure of kisspeptin is a key starting point for this endeavour. Systematic substitu tion of each of the amino acids of Kp10 was performed to determine a consensus sequence for analogues that retained binding but failed to elicit signalling, and antagonized Kp10 stimulation of downstream signal ling pathways in cells expressing the human GPR54. 110 The major conclusions of the studies are summarized in Figure 6 . Importantly, substitution of serine 5 with the achiral glycine seemed to create flexibi lity within the peptide and improved tolerance of other substitutions directed at antagonism. Replacement of leucine 8 with dtryptophan was also valuable for antagonism. In an attempt to reduce degradation, the amino terminus of the peptides was acetylated.
Antagonists with these key features exhibited high binding affinity and potency in inhibiting kisspeptin stimulation of the production of inositol phosphates in cells expressing the human GPR54. Numerous other peptide analogues have been synthesized, including those containing substitutions with unnatural amino acids, which confirmed the general consensus sequence for antagonist structure. To confer blood-brain barrier permeability, a penetratin sequence was added to the amino terminus of one of the antagonists, 234.
Smallmolecule nonpeptide kisspeptin antagonists derived from a 2acylamino4,6diphenylpyridine scaf fold have also been developed. 118 Kobayashi et al. iden tified compound 15a, which exhibited high binding affinity for GPR54 and antagonism of kisspeptin in vitro and in vivo (Figure 6 ).
118,119

REVIEWS Interrogating kisspeptin's role in physiology
The efficacy of the peptide antagonists was established by the demonstration of their capacity to inhibit kisspeptin stimulation of LH secretion in rats and the LH increase after castration of mice. 110 Peptide antagonist 234 was also effective in suppressing LH (GnRH) pulsatility in ovariec tomized ewes. 110 However, in all these models, kiss peptin antagonists did not reduce levels of LH to below basal levels of intact animals, unlike GnRH antagonists, which suggested that a component of GnRH secretion is indepen dent of kisspeptin. Antagonist 234 directly inhibited kisspeptin stimulation of GnRH neuron firing in mouse brain slices at low concentration (1 nM) and, in pubertal female rhesus monkeys, it inhibited GnRH pulses but not basal levels. 110 This finding provides direct evidence for a role of kisspeptin in GnRH secretion at puberty in mammals. In another study in prepubertal female monkeys, GnRH was suppressed for a longer period of 90 min by antagonist 234, which suggested that endogenous kisspeptin secretion is lower prepubertally. 120 Antagonist 234 also decreased LH pulse frequency, but not basal LH secretion, when administered directly into the hypothalamic ARC in ovariectomized female rats. 121 This finding suggests that kisspeptin is a component of the GnRH pulse generator in the ARC. Antagonist 234 also delayed puberty in female rats, 117 which together with the effects on GnRH pulse frequency in pubertal and prepubertal monkeys confirmed a role for kiss peptin in puberty, which had previously been suggested by the failure to progress through puberty in patients with GPR54 and kisspeptin mutations. 6, 7 Further studies with antagonist 234 also demon strated that kisspeptin is required for the elevation of LH levels when removing negative sex steroid feedback by orchidectomy of sheep and laboratory rodents. 110 The positive feedback of estro gen in the LH ovulatory surge in female rats was also shown directly to be kisspeptin dependent, as antagonist 234 inhibited this surge. 117 Smallmolecule kisspeptin antagonists such as 15a ( Figure 6 ) can penetrate the blood-brain barrier. Similarly, peptide 271, a modified version of peptide 234, which has a penetratin sequence attached to convey brain penetration, was able to inhibit the LH stimulation by intracerebroventricular kisspeptin when it was admini stered systemically to rats 117 and inhibited the LH surge in ewes. 122 A comparison of the effects of these brain penetrant and nonpenetrant kisspeptin antagonists on LH stimulation by systemic and intracerebroventricular administered kisspeptin might shed light on the potential sites of action of kisspeptin on GnRH neuron cell body, axons and nerve terminals.
In summary, kisspeptin antagonists are powerful tools for demonstrating the physiological role of kiss peptin in GnRH neuron firing and GnRH pulsatility, in positive and negative feedback by gonadal steroids, in the LH surge of ovulation and in puberty. Kisspeptin antagonists have also highlighted that GnRH secretion is not entirely dependent on kisspeptin, as basal GnRH and LH were unaffected by kisspeptin antagonist in these studies. These studies demonstrate that kisspeptin antagonists may be effectively used to interrogate the role of kiss peptin in other physiological paradigms, such as the effects of leptin, inhibin, activin, follistatin, nutri ents and the dialogue between kisspeptin, neurokinin B and dynorphin A in the secretion of GnRH and LH. The antagonists might also be used to interrogate kiss peptin's role in the placenta and in the CNS, for example, its effects on behaviour.
Potential therapeutic applications
The effects of native Kp54 and Kp10 have been exten sively studied in humans. Kp54 stimulated the secretion of gonadotropins in healthy women and in women with hypothalamic amenorrhea; however, longterm treatment induced tachyphylaxis. 123 Administration of Kp54 to pre menopausal women with regular menstrual cycles showed the greatest gonadotropin response during the preovula tory phase of the menstrual cycle and the least response during the follicular phase. 91 Postmenopausal women had a greater LH response to Kp10 than women in the follicular phase of the menstrual cycle and women with progestogen implants, whereas women on the combined contraceptive pill did not have a signi ficant response, in dicating a greater degree of negative feedback. 124 Acute administration of Kp54 or Kp10 to healthy men elicited robust stimulation of gonadotropin secretion, 88, 90 and continuous infusion of Kp10 for 22.5 h increased gonadotropin secretion and pulse frequency, with no tachphylaxis over this period. 90 Continuous Kp10 infu sion had similar effects on LH in men with type 2 dia betes mellitus, in whom low serum testosterone levels are commonly observed, and restored testos terone levels to within the normal range. 125 These findings suggest that longacting formulations of Kp10 or synthetic agonists (see below) might find utility in men with hypogonadism and for the induction of ovulation. On the other hand, the finding that longterm treatment with kisspeptin ago nists can induce more rapid and profound inhibition of testos terone than the GnRH agonist leuprorelin in male rats suggests that agonists might also be used for steroid hormone ablation to castration levels in the treatment of prostate and breast cancers. 114 As mentioned earlier, GnRH analogues are used widely for the treatment of hormonedependent dis eases and in IVF, either through gonadotrope desensiti zation with GnRH agonists or through the use of GnRH anatgonists to prevent GnRHR activation by endo genous GnRH. These treatments result in suppression of gonadotropin secretion and consequent reduction in gonadal steroid hormones to castrate levels. This reduc tion to castrate levels can lead to adverse effects such as hot flushes, reduced lean body mass, loss of libido and bone loss. Although kisspeptin antagonists reduce LH pulsa tility 110, 121 and inhibit the ovulatory LH surge, 117 they do not seem to lower basal LH secretion. Therefore, kiss peptin antagonists might be employed as partial inhibitors of gonadotropin and sex steroid secretion in conditions where maximal suppression of sex steroids is contra indicated. Examples are benign prostatic hyper plasia, endometriosis and uterine fibroids, where lower ing of gonadal steroids could improve the conditions without adverse effects. PCOS, which is characterized by increased LH pulse frequency and an increased ratio of LH to FSH, is another potential target of kisspeptin therapy. Although unproven, reduction of GnRH pulse frequency by kiss peptin antagonists should maintain FSH levels (favoured by a low GnRH pulse frequency) whilst reducing LH levels, as desired in women with PCOS. The reduc tion in LH pulse frequency by kisspeptin antagonists in animal studies and increase in LH pulse frequency by con tinuous kisspeptin administration in human studies 90, 110, 111, 125 supports the possibility of this thera peutic approach for PCOS. Furthermore, the putative effect of antagonists on increasing the ratio of FSH to LH would allow follicle development and estrogen pro duction but inhibit ovulation, making kisspeptin antago nist administration an interesting possibility as a female contra ceptive. Kisspeptin antagonists might also find application in IVF to prevent premature luteinization whilst maintaining basal LH levels, which might be of value in some women during superovulation. 126, 127 In summary, the discovery of kisspeptin antagonists provides a new avenue for investigating the role of kiss peptin in the normal physiology and pathophysiology of gonadotropin regulation. Kisspeptin analogues also have potential therapeutic value for the treatment of hormonedependent diseases without generating the adverse effects of current therapeutics that induce total ablation of gonadal steroids.
Neurokinin B analogues
Background Neurokinin B (also known as neuromedin K or neuro kinin 3) has emerged as a novel neuropeptide with a crucial role in the neuroendocrine regulation of repro duction. In 2009, inactivating mutations in the human genes encoding neurokinin B and its cognate receptor TACR3 (also known as NK3R), were shown to result in failure to progress through puberty and in hypo gonadotropic hypogonadism in adulthood.
9-11 By con trast, the original study of an inactivating mutation in the Tacr3 gene that encodes TACR3 in mice, did not report reproductive impairment. 128 However, a subsequent study showed that this mouse model partially recapitu lates the phenotype in humans. 129 Numerous studies on the role of neurokinin B in rodents have been conducted that reveal apparently contradictory findings and a more complex role for the neuropeptide. These studies will not be reviewed here, but the reader is referred to a compre hensive review. 130 Other studies in monkeys, 131 goats 132 and sheep 133 show a clear stimulatory role of neuro kinin B in gonadotropin secretion, in keeping with the observations in humans of decreased LH secretion in the absence of neurokinin B signalling. Patients with inactivat ing mutations of genes encoding neurokinin B or its receptor were characterized by very low levels of LH but normal or nearnormal circulating FSH levels. 9 This picture is in keeping with a low GnRH pulse frequency. 134 By contrast, inactivating mutations in GPR54 result in low levels of both LH and FSH. 6, 7 Thus, loss of kisspeptin signalling was suggested to lead to a major loss of GnRH pulsatility, whilst loss of neurokinin B signalling leads to lowfrequency GnRH pulsatility. 135 Kisspeptin neurons in the ARC have been shown to coexpress neurokinin B and dynorphin A 132, [136] [137] [138] and have, therefore, been named KNDY neurons. 136 As GnRH neurons express GPR54 but apparently not TACR3, 133, 138, 139 whereas KNDY neurons express TACR3 but not GPR54, it was further postulated that neuro kinin B secreted from KNDY neurons acts in an auto crine or paracrine manner to enhance kisspeptin secretion and that neurokinin B actions were upstream of kisspeptin. 135 This notion was supported by the demon stration that continuous infusion of kisspeptin at a GPR54saturating concentration in patients with neuro kinin B and TACR3 inactivating mutations restored LH pulsatility. 135 The conclusion that neurokinin B operates upstream of kisspeptin in humans is in agreement with studies in monkeys 131 and goats. 132, 139 The positioning of neurokinin B actions upstream of kisspeptin raises the possibility that modulation of neuro kinin B signalling with agonists and antagonists will be more subtle than analogue modulation of kiss peptin signalling, which in turn is more subtle than modula tion of GnRH signalling. This being the case, distinct opportunities exist for the development and utilization of drugs that target the three levels of the neuroendocrine cascade with differential effects on gonado tropin and steroid hormones.
Neurokinin B and peptide analogues
Neurokinin B is a decapeptide (Figure 7) , which is cleaved from a precursor protein. It is a member of the tachykinin family of peptides that are characterized by a common carboxylterminal motif: PheXGlyLeu MetNH 2 . Receptor affinities of the different tachykinins are specified by variations in the amino terminal domain of the peptide. Neurokinin B was first identified in the 1980s as a substancePrelated peptide in porcine spinal chord. 140 Neurokinin B interacts with all three mamma lian GPCR tachykinin receptors (TACR1, TACR2 and TACR3) but has highest selectivity for TACR3. This tachy kinin receptor, which is selective for neuro kinin B, was first identified through binding studies in mamma lian CNS and functional studies using guinea pig ileum, [141] [142] [143] leading to the cloning of human TACR3. 144 A number of tachykinin analogues exist, and the majority of these have selectivity for TACR1 or TACR2. However, some analogues have been developed that are highly selective for TACR3. As the importance of neurokinin B in the neuroendocrine control of repro duction has only become clear in the past 5 years, the thera peutic targets for TACR3selective antagonists have generally been in the CNS field (for example, schizo phrenia, anxiety, pain, inflammation) and also in some pul monary diseases (for example, chronic obstructive pulmonary disease) and gastrointestinal tract diseases (for example, irritable bowel syndrome). The develop ment of these analogues fortuitously provides an oppor tunity to utilise these agents to delineate the role of neurokinin B in reproduc tive neuroendocrinology and as potential therapeutics in this area.
The first TACR3selective peptide agonist, senktide, was developed by systematic methylation of the peptide bonds in a truncated version of the TACR1selective tachykinin, substance P. Senktide (Figure 7) , in which the phenylalanine at position 8 is methylated, was found to have very high selectivity for TACR3 compared with neurokinin B. 145 In addition, this modified peptide also had much higher metabolic stability than the native tachykinins, making it a useful experimental tool. 146 An analogue of neurokinin B in which the valine at posi tion 7 has been replaced with methylphenylalanine in a similar way also retains high affinity for the TACR3 and has improved selectivity for TACR3 over the other tachykinin receptors (Figure 7) . 147 Replacing valine at position 7 of neurokinin B with proline also improves selectivity for the TACR3. 148 Screening and optimization of a dipeptide library has also led to the development of 'peptoid' antagonists, PD157672 and PD161182, with high selectivity for TACR3. 149 Nonpeptide antagonists Several nonpeptide TACR3selective antagonists have been developed. These fall into two main structural classes: dichlorophenylalkylpiperidines (for example, osanetant) and quinolones (for example, talnetant). Osanetant was developed by modification of a com pound selective for the TACR2 receptor, saredudant, and was the first highaffinity nonpeptide TACR3selective antagonist to be described (Figure 7) . [150] [151] [152] [153] Modified analogues of osanetant have since been developed. 154, 155 Differentially substituted 4quinoline carboxyamides have been identified as TACR3selective antagonists that displayed similar potency but increased TACR3 selectivity compared with osanetant. 156 Modifications to optimize these initial compounds led to the identifica tion of talnetant, an orally active, potent and selective TACR3 antagonist. [157] [158] [159] Analogues of talnetant, with increased blood-brain barrier permeability 160, 161 or no blood-brain barrier permeability, 162 have since been described, and other talnetantbased TACR3 antago nists, including AZD2624 and compound 8m, have been developed. 163, 164 One of the biggest problems with preclinical testing of these TACR3 antagonists is their species selectivity, with compounds from both chemical classes displaying 10fold to 100fold higher affinity for the human TACR3 than for the mouse or rat receptor, thus making their testing in relevant preclinical disease models difficult. Potential therapeutic applications Although TACR3 antagonists have not been clinically tested for reproductive effects, osanetant, talnetant and AZD2624 have been the subject of several clinical trials to assess their effectiveness in treating CNS disorders (for example, schizophrenia, anxiety and depression) and other nonCNS indications (for example, irritable bowel syndrome or overactive bladder). Although initial trials provided promising data on the use of these compounds for the treatment of schizophrenia, subsequent trials have been inconclusive. As a result, clinical development of most of these TACR3 antagonists for the treatment of CNS disorders has been discontinued. 166 The probable absence of CNS adverse effects associated with TACR3 antagonists (as assessed in regulatory trials in humans) is a distinct advantage in their utilization for the inhibition of reproductive hormones.
Neurokinin B agonists and antagonists have potential as therapeutics for the treatment of various dysfunc tions of the reproductive system. As mentioned earlier, the upstream position of neurokinin B suggests that analogues of neurokinin B will have more subtle effects than those of kisspeptin analogues, which in turn will have more subtle effects than those of GnRH analogues. Consequently, use of neurokinin B antagonists, or desen sitization with agonists, will potentially lower LH levels less than kisspeptin or GnRH analogues and have little effect on FSH levels, as is evident in patients with defi ciencies in neurokinin B signalling. This property might be valuable in the treatment of hormonedependent dis eases, such as endometriosis and benign prostatic hyper plasia, which require partial inhibition of sex st eroids and the avoidance of adverse effects such as bone loss, loss of libido and hot flushes that are charac teristic of GnRH analogue treatment. In addition, in conditions of decreased LH production and nearnormal FSH secre tion resulting from low GnRH pulse frequency, such as in patients with hypothalamic amenorrhea or delayed puberty, 167 restoration of LH levels and normal repro ductive function could potentially be achieved by treat ment with neurokinin B (or kisspeptin) agonists. In conditions characterized by high LH pulse amplitude and frequency, such as PCOS, 168 neurokinin B antago nists might be effective in lowering LH levels without affecting FSH levels, thus restoring the LH:FSH ratio. Neurokinin B antagonists might also have potential as a novel type of female contraception, as disruption of neurokinin B signal ling maintains FSH levels but reduces levels of LH and would, therefore, potentially prevent ovulation. Similar to kisspeptin agonists, neurokinin B agonists might also be useful in providing a milder stimulation of gonadotropins in assisted reproduction technologies than that achieved with GnRH analogues.
Because of the partial inhibition of sex st eroids by these analogues, they are unlikely to be of value in treating hormone dependent cancers, such as prostate cancer, in which reduction of sex steroids to castration levels is a pre requisite for ef ficacy, as accomplished with GnRH analogues.
A potential limitation in the therapeutic use of neuro kinin B agonists is tachyphylaxis, which has been reported in monkeys. 131 However, this limitation could be an issue of time and dose, as tachyphylaxis has also been observed in longterm administration of Kp54 to women with hypothalamic amenorrhea 123 and in juve nile 169 and adult 170 monkeys, but it was not observed in men receiving continuous infusion of Kp10 at near maximal LHstimulating levels over 22 h. 90 
Conclusions
Reproductive hormones have an important role at all stages of life, from gamete production and fertilization, through puberty and adulthood to senescence. The hormone cascade of brain neuroendocrine peptides, gonadotropins and steroid hormones are all targets for the development of analogues for intervention in normal physiological and pathophysiological processes. GnRH peptide antagonists and agonists (through desensitiza tion) are widely employed to reduce levels of sex steroids and thereby treat diverse hormone-dependent diseases (for example, prostate cancer) and in assisted reproduc tive technologies (for example, IVF). However, these analogues lower sex steroids to castration levels in the treatment of cancers, causing adverse effects such as bone loss. The development of smallmolecule, orally active GnRH antagonists has presented the opportunity of titrating dose to partially inhibit steroids to treat condi tions such as endometriosis and benign prostatic hyper plasia without eliciting adverse effects. The dis covery of novel neuroendocrine analogues of kisspeptin and neurokinin B, which are upstream regulators of GnRH secretion, provide further therapeutic options, as their more proximal position in the cascade holds promise for more subtle interventions.
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